 Home > Chemicals Industry > China Chemical > The pharmaceutical machinery industry faces two major pain points, and transformation and upgrading are the key

The pharmaceutical machinery industry faces two major pain points, and transformation and upgrading are the key

 Last Update: 2022-06-21
 Source: Internet
 Author: User

Tags

laboratory centrifuge

paregoric medicine

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Focus on Chemical Machinery Equipment Network ] In recent years, with the development of science and technology and the continuous maturity of domestic pharmaceutical technology, the types of domestic pharmaceutical equipment have been continuously enriched, which can basically meet the needs of pharmaceutical companies.
However, with the increasing production requirements of pharmaceutical companies, the industry has generally recognized that China's pharmaceutical equipment industry has the problems of insufficient equipment and lack of high-tech pharmaceutical equipment manufacturers.

Chemical machinery and equipment network hotspots pay attention to chemical machinery and pharmaceutical equipment

In order to promote the high-quality development of the pharmaceutical industry, domestic pharmaceutical equipment companies and even the entire industry urgently need to transform and upgrade in the direction of intelligence and informatization.

The industry faces two major pain points, transformation and upgrading are the key

Insufficient equipment and lack of high-tech pharmaceutical equipment manufacturers can be said to be the two major pain points facing the pharmaceutical machinery industry.

At present, domestic pharmaceutical machinery and equipment mainly open the market with advantages such as low price and convenient maintenance, but they are mainly concentrated in the middle and low-end fields, while equipment such as centrifuges and other products are mainly monopolized by imported products*.

Centrifuge

　　At the same time, the domestic pharmaceutical equipment industry is not highly concentrated, and the overall situation is small, scattered, and chaotic.
Most of the enterprises are small and medium-sized, with weak independent innovation, low technical content, and lack of perseverance and excellence.

　　Analysis of the reasons behind it is closely related to factors such as the lack of core technology, the shortage of R&D funds due to the small size of the enterprise, and the shortage of professional talents.

　　Since 2020, affected by the normalization of centralized procurement and the promotion of consistency evaluation, the pharmaceutical market structure has intensified changes, and pharmaceutical companies are facing the challenges of rising costs and expanding production capacity.
Recently, * also proposed to accelerate the high-quality development of the pharmaceutical industry.
It can be said that the transformation and upgrading of the pharmaceutical machinery industry is imminent.

　　Some companies have moved towards the field

　　Aiming at the larger development space of the domestic pharmaceutical equipment market, at present, some enterprises with innovative capabilities have moved towards the field of intelligence and made some progress.

　　For example, Xinma Pharmaceutical's pharmaceutical equipment industrialization project is gradually advancing and is expected to be officially put into operation by the end of this year.
The start of the project marks the further upgrading of the technological innovation of Xinma Pharmaceutical.
At the same time, the company will form a solid preparation-laboratory, customized, production-type, and closed-type production line of the whole industry chain, and become a stable and reliable solid for domestic and foreign customers.
A complete solution provider for preparation equipment.

　　Xinma Pharmaceutical said that it is confident that with the construction of this project, the level and competitiveness of the domestic pharmaceutical equipment industry will be improved, and the pain points of the domestic pharmaceutical equipment industry will be solved.

　　No* occasionally, Canaan Technology announced the establishment of a wholly-owned subsidiary Zhejiang Canaan Health Technology Co.
, Ltd.
in May this year to promote the investment and construction of the Wenzhou Smart Factory project industrial base.
On the same day, it announced that it plans to participate in the bidding for the right to use the state-owned construction land for Yongjia County Gong 202006 not to exceed 55 million yuan.

　　Relying on this industrial base, the company stated that it will continue to strengthen the core competitiveness of the three business segments of the generic solid preparation smart factory business, biological preparation innovative medicinal water equipment and pharmaceutical liquid dispensing system engineering business, and smart logistics business, and create supporting data operations.
Center; to establish research and manufacturing capabilities for smart pharmaceutical equipment and smart logistics systems that meet the needs of the domestic market, form a more complete industrial chain, and further expand the company's business scale.

　　In addition, Chutian's tens of billions of production capacity and the fourth phase of the construction of the project are also in progress.
The project site will build Chutian Science and Technology Innovation Center Building, Talent Center Building, * Workshop, Intelligent Chinese Medicine Workshop, Intelligent Backpack Workshop, Chutianyuan Creation Workshop, Apartment Building E Building and other R&D, manufacturing and management units and living supporting facilities.
.
The total investment of the project is 1.
2-1.
6 billion yuan.
It is planned to start construction at the end of April and complete the construction in 3-4 years, which will lay a more solid foundation for Chutian Technology to build a medical equipment enterprise.

　　Innovation is the vitality of an enterprise.
In terms of R&D investment and talent training, Chutian is a company that is very willing to "spend money" in the industry.
According to the company's semi-annual report, the company's expenses during the first half of the year were 279 million yuan, an increase of 33.
473 million yuan over the same period last year, an increase of 13.
63%.
The company explained that the main reason was that on the one hand, the company adjusted the salary of a group of core employees; on the other hand, the company introduced a group of technical management talents and provided preferential treatment to enhance its core competitiveness, resulting in a higher salary cost than the previous year.
Increased over the same period.

　　In the future, domestic medicine machines may accelerate import substitution

　　Although domestic pharmaceutical machinery companies are mainly small and medium-sized enterprises, some companies have already accumulated rich experience and market resources due to their early start in the industry and long-term cooperation, and they have more forward-looking vision in long-term planning.
Including speeding up the import substitution of domestic medicine machines.

　　At the 2020 Shanghai Biological Fermentation Exhibition held a few days ago, many pharmaceutical machinery companies have shown their confidence in the development of domestic pharmaceutical machinery products.

　　For example, some high-tech companies that provide a series of services in various fields such as pharmaceuticals, daily chemicals, health care products, etc.
, said that the company is currently cooperating with overseas companies to introduce excellent products and services to domestic customers.
Through continuous learning, we will try our best to introduce some excellent products into the country, and then carry out independent research and development and production.

　　"It is worth noting that through the comparison of experimental data, we can draw a conclusion that the products produced by our Chinese companies are completely comparable to imported brands.
" The company said.

　　There are also biological equipment suppliers who specialize in providing biological reaction processes and control.
Looking forward to the future, the company will explore new markets in more fields.
"For example, in the monoclonal antibody industry that has been booming in the past two years, almost all the equipment used in this industry currently depends on imports.
Our goal for ourselves is to use our domestic equipment to gradually replace imports in 5-10 years.
product.
"

　　Concluding remarks

　　On the whole, the road to the industrialization of domestic pharmaceutical equipment is still very long.
It requires the industry, the company, and every pharmaceutical company to strengthen their conviction and confidence, strengthen their independent innovation capabilities, and continue to work hard to break through the bottleneck.
At the same time, the industry also pointed out that the pharmaceutical equipment industry, as a complex subject involving many aspects, will have higher and higher professional technical requirements in the process of transformation and upgrading.
Therefore, enterprises need to strengthen their attention to talents.
.

　　Original title: Insufficient equipment and lack of high-tech enterprises, the transformation and upgrading of the pharmaceutical machinery industry is the key

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.